Press Releases

Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer  PONTE VEDRA, Florida – May 17, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Matthew K. Szot as the Company’s Chief Financial Officer (“CFO”). Szot brings more than 25 years of executive-level financial experience to Cadrenal, having been the CFO of S&W Seed Company (NASDAQ: SANW), a

Cadrenal Therapeutics Acquires Tecarfarin from Horizon PONTE VEDRA, Florida – April 1, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”) has acquired the rights to tecarfarin from Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The new company is headed by Founder and Chief Executive Officer Quang Pham